Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress
Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress
- Treatment with AFM28 innate cell engager (ICE), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse model
- AFM28 led to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells in a newly engineered ex vivo bone marrow niche model
- 使用旨在靶向急性髓系白血病 (AML) 患者的 CD123 陽性癌細胞的 AFM28 先天細胞活化劑 (ICE) 進行治療，在經過驗證的體內小鼠模型中實現了劑量依賴性腫瘤生長控制
- 在新設計的體外骨髓利基模型中，AFM28 有效減少了表達 CD123 的急性髓細胞白血病患者衍生的白血病細胞和幹細胞
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.
德國曼海姆，2024年5月14日（GLOBE NEWSWIRE）——致力於讓患者恢復與生俱來的抗癌能力的臨床階段免疫腫瘤學公司Affimed N.V.（納斯達克股票代碼：AFMD）今天宣佈發佈將於2024年6月13日至16日在西班牙馬德里舉行的歐洲血液學協會（EHA）年會的摘要。該摘要提供了Affimed在急性髓系白血病（AML）小鼠異種移植模型中靶向CD16a/CD123的ICE AFM28 的臨床前數據，並表明增加 AFM28 劑量會導致劑量依賴性腫瘤生長控制，與對照組相比，接受治療的小鼠的中位壽命延長。
In addition, the abstract shows a data set from a collaboration with Dr. Hind Medyouf's group at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany. In a newly engineered ex vivo Human Organotypic Marrow Environment (HOME) model, the combination of AFM28 and allogeneic NK cells can lead to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells. Importantly, the HOME model exhibits key immune suppressive cellular components, i.e. mesenchymal niche cells, enhancing the translational relevance of AFM28 preclinical activity.
此外，摘要顯示了與德國美因河畔法蘭克福Georg-Speyer-Haus腫瘤生物學和實驗治療研究所Hind Medyouf博士團隊合作的數據集。在新設計的體外人類器官型骨髓環境 (HOME) 模型中，AFM28 和異體 NK 細胞的組合可以有效減少表達 CD123 的急性髓細胞白血病患者衍生的白血病細胞和幹細胞。重要的是，HOME 模型表現出關鍵的免疫抑制細胞成分，即間充質利基細胞，增強了 AFM28 臨床前活性的翻譯相關性。
譯文內容由第三人軟體翻譯。